Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nuvisertib in Intermediate or High-Risk Myelofibrosis
NCT04176198Phase 2Recruiting
- Sponsor
- Sumitomo Pharma America
- Start
- Dec 2019
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of nuvisertib in myelofibrosis (MF), sponsored by Sumitomo Pharma America. Started Dec 2019; status: recruiting.
02
Drugs
nuvisertib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04176198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04176198.